Report Subject - Technology/Digital Health - Page 1

Learn More Pricing and Reimbursement in Respiratory: Payer Views [2020]

How have payers met the challenge of COVID-19 and how do they see the future? The impact of the COVID-19 pandemic has been especially felt in respiratory disease and presents a unique set of challenges for payers. From...

Compare
Learn More Innovations in Drug Pricing and Reimbursement 2020

Evaluating new digital tools and deal structures to drive better commercial outcomes What are the trends and technologies that could deliver a better understanding of payers' needs and build improved evidence of value?...

Compare
Learn More Data Driven Customer Relationship Management In Pharma

Experts agree data-driven CRM holds the key to achieving true customer centricity It's already known that data-driven CRM improves and drives forward the customer experience. Pharma has a powerful tool at its disposal,...

Compare
Learn More Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge

Creating meaningful insights from diverse data sources The explosion in real-world data (RWD) from digital platforms is creating new insights into the understanding of rare diseases and patient experiences. The value...

Compare
Learn More Pricing and Reimbursement in Neurology: Payer Views [2020]

Understanding payer challenges in Multiple Sclerosis, Epilepsy, Migraine and Neurodegenerative disease Despite wide unmet need across a number of neurological conditions, no really high impact breakthrough therapies...

Compare
Learn More Value-based Healthcare in a Digital World [2020]

Accelerated use of digital technology challenges pharma to rethink its approach COVID-19 has radically increased the use of digital technology by patients and HCPs but how does that play into the trend to value-based...

Compare
Learn More Orphan Drugs: Benchmarking Commercial Models [2020]

What are the essential factors for orphan drug success? Several orphan drugs have proven to be commercial winners, so what are the key ingredients for success in 2020? For example, as the sector has evolved the power...

Compare
Learn More MSL-KOL Engagement [2020]

Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...

Compare
Learn More The Rise of ICER – The Payer Perspective

Payers reveal where ICER is really impacting pharma/payer relations How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by...

Compare
Learn More The State of Pharma Digital Transformation 2020

How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...

Compare
Learn More Smart Pharma Sales: How Digital is Reinventing the Process

Post COVID-19, pharma's opportunity is to build on the impact of digital technology to revolutionize its sales practice and engagement strategies The COVID-19 pandemic has radically reshaped how pharma does sales and...

Compare
Learn More Engaging with ICER: Lessons and insights for pharma

ICER is here to stay so how best can industry engage for its benefit? The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and...

Compare
Learn More Digital Health and the Management of Chronic Disease

Essential strategies for developing next phase digital health solutions The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become...

Compare
Learn More Measuring Digital Success in Pharma: Essential KPIs

Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...

Compare
Learn More Biosimilars: US Payer Insights 2020

What do payers see as unlocking the sluggish US biosimilar market? Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector...

Compare
Learn More Drivers of Non-medical Rx Switching

The strategies that are promoting wider use of biosimilars Payers are highly motivated to realise the cost savings of biosimilars, but what strategies are they using to reassure and encourage physicians and patients?...

Compare

Browse by